Patents Assigned to St. Jude Children's Research Hospital
  • Patent number: 11560548
    Abstract: The present invention provides, in certain aspects, a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15), and methods for producing such cells. The invention further provides methods of using a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15) to treat cancer in a subject or to enhance expansion and/or survival of NK cells.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: January 24, 2023
    Assignees: National University of Singapore, St. Jude Children's Research Hospital, Inc.
    Inventors: Dario Campana, David Shook, Masaru Imamura
  • Publication number: 20230016709
    Abstract: Methods for detection, diagnosis, prognosis, theragnosis, and targeted therapy of a PRSS21-overexpressing condition (e.g., cancer), in particular, PRSS21-overexpressing acute myeloid leukemia of the AMKL subtype.
    Type: Application
    Filed: November 24, 2020
    Publication date: January 19, 2023
    Applicant: St. Jude Children's Research Hospital
    Inventors: Stephen Gottschalk, Patrick Schreiner, Yiping Fan, Nikhil Hebbar, Myreya Paulina Velasquez
  • Publication number: 20230021224
    Abstract: In one aspect, the invention relates to substituted 1-phenyl-3-(piperidin-4-yl)urea analogs, derivatives thereof, and related compounds, which are useful as inhibitors of the DCN1-UBC12 interaction inhibitors of DCN1-mediated cullin-RING ligase activity, methods of making same, pharmaceutical compositions comprising same, methods of treating disorders using the disclosed compounds and compositions, methods of treating disorders associated with a DCN1-UBC12 interaction dysfunction, methods of treating disorders associated with a DCN1-mediated cullin-RING ligase activity dysfunction, methods of male contraception comprising the disclosed compounds and compositions, and kits comprising the disclosed compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: September 9, 2021
    Publication date: January 19, 2023
    Applicants: MEMORIAL SLOAN KETTERING CANCER CENTER, ST. JUDE CHILDREN'S RESEARCH HOSPITAL
    Inventors: Jaeki MIN, Daniel C. SCOTT, Deepak BHASIN, Brenda A. SCHULMAN, Bhuvanesh SINGH, Jared T. HAMMILL, R. Kiplin GUY
  • Patent number: 11547709
    Abstract: The present disclosure relates to methods of treating a coenzyme A reduction, elevation, sequestration, toxicity, or redistribution (CASTOR) disease such as, for example, defects in fatty acid oxidation enzymes, methylmalonic acidemia, glutaric acidemia, propionic academia, and HMG-CoA lyase, via small molecule modulators of CoA levels. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: December 26, 2018
    Date of Patent: January 10, 2023
    Assignees: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC., COA THERAPEUTICS, INC.
    Inventors: Suzanne Jackowski, Charles O. Rock, Richard E. Lee, Lalit Kumar Sharma, Mi Kyung Yun, Chitra Subramanian, Rajendra P. Tangallapally, Anne V. Edwards, Robert Zamboni, T. Jagadeeswar Reddy, Jiuyu Liu
  • Publication number: 20230000881
    Abstract: In one aspect, pharmaceutical compositions comprising a CDK2 inhibitor and one or more of at least one agent known to treat a hearing impairment and at least one agent known to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: July 12, 2022
    Publication date: January 5, 2023
    Applicant: St. Jude Children's Research Hospital
    Inventors: Jian Zuo, Tal Teitz, Fang Jie, Goktug Asli, Chen Taosheng, Min Jaeki, R. Kiplin Guy
  • Publication number: 20220406435
    Abstract: Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile.
    Type: Application
    Filed: August 18, 2022
    Publication date: December 22, 2022
    Applicant: St. Jude Children's Research Hospital
    Inventors: Ida Annunziata, Alessandra D'Azzo, Shai White-Gilbertson
  • Publication number: 20220378896
    Abstract: Compositions and methods are provided for reducing the mammalian transmission of Streptococcus pneumoniae (S. pneumoniae) through the administration to mammalian subjects of vaccine compositions comprising at least one immunogenic polypeptide comprising a S. pneumoniae protein or a fragment or variant thereof that is required for or involved in transmission of the bacteria between mammalian hosts. These vaccine compositions also serve to reduce the incidence rate of at least one invasive disease caused by S. pneumoniae. Methods are also provided for identifying additional genetic factors involved in mammalian transmission of S. pneumoniae.
    Type: Application
    Filed: March 12, 2020
    Publication date: December 1, 2022
    Applicant: St. Jude Children's Research Hospital
    Inventors: Jason W. Rosch, Hannah M. Rowe
  • Publication number: 20220326216
    Abstract: The application provides T cell gene expression signatures that can be used to predict T cell therapy outcomes.
    Type: Application
    Filed: April 8, 2020
    Publication date: October 13, 2022
    Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.
    Inventors: Benjamin YOUNGBLOOD, Jeremy CRAWFORD, Yiping FAN, Caitlin ZEBLEY, Stephen GOTTSCHALK, Giedre KRENCIUTE, Christopher PETERSEN
  • Publication number: 20220288235
    Abstract: Described is a method for treating a social memory deficit in a subject with a neuropsychiatric disease is treated by administering a peptide encoded by 2510002D24Rik or Atp23 genes, a vector expressing such peptide, or an agent capable of increasing the level or activity of such peptide. The method may be used to treat schizophrenia or autism. The peptide, vector or agent can be administered directly to the hippocampus, such as by transcranial surgical injection.
    Type: Application
    Filed: August 19, 2020
    Publication date: September 15, 2022
    Applicant: St. Jude Children's Research Hospital, Inc.
    Inventors: Stanislav S. ZAKHARENKO, Prakash DEVARAJU
  • Publication number: 20220280488
    Abstract: A DCN1/2-mediated cullin neddylation modulator; a method for treating disorders associated with dysfunctional DCN1 and/or UBC12, Alzheimer's disease, other neurodegenerative diseases, bacterial infections, or viral infections; and a method for treating cancers are provided. The DCN1/2-mediated cullin neddylation modulator includes a compound according to Formula I disclosed herein. The methods include administering to a mammal a therapeutically effective amount of a compound according to Formula I. Also provided herein is a pharmaceutical composition including a therapeutically effective amount of a compound according to Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: June 22, 2020
    Publication date: September 8, 2022
    Applicants: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, MEMORIAL SLOAN-KETTERING CANCER CENTER, St. Jude Children's Research Hospital, Inc.
    Inventors: Hoshin KIM, Rodney Kiplin GUY, Jared T. HAMMILL, Daniel Charles SCOTT, Benda Arlene SCHULMAN, Bhuvanesh SINGH
  • Publication number: 20220267425
    Abstract: The application relates to a chimeric antigen receptor that directly and/or indirectly targets cells and their uses in tumor immunotherapy. The application also relates to polynucleotides that encode the chimeric antigen receptor and optionally accessory genes, vectors, and host cells comprising the chimeric antigen receptor and optionally a second antigen targeting moiety (e.g., a second chimeric antigen receptor or a bispecific molecule). The application also relates to methods for preparing host cells comprising the chimeric antigen receptor and optionally the second antigen targeting moiety.
    Type: Application
    Filed: July 17, 2020
    Publication date: August 25, 2022
    Applicant: St. Jude Children's Research Hospital, Inc.
    Inventors: Stephen Gottschalk, Jessica Wagner, Timothy Isham Shaw, Jinghui Zhang
  • Patent number: 11419920
    Abstract: There is provided a nucleic acid molecule comprising a nucleotide sequence encoding a Factor VIII protein, wherein a B domain portion of the Factor VIII protein is encoded by a nucleotide sequence between 90 and 111 nucleotides in length and has an amino acid sequence that is at least 85% identical to SEQ ID NO: 4 which comprises six asparagine residues. Also provided is a Factor VIII protein, a vector comprising the above nucleic acid molecule, a host cell, a transgenic animal, a method of treating Haemophilia for example, Haemophilia A, and a method for the preparation of a parvoviral gene delivery vector.
    Type: Grant
    Filed: September 2, 2020
    Date of Patent: August 23, 2022
    Assignees: UCL BUSINESS LTD, ST. JUDE CHILDREN'S RESEARCH HOSPITAL
    Inventors: Amit Nathwani, Jenny McIntosh, Edward Tuddenham, Andrew Davidoff
  • Publication number: 20220249604
    Abstract: Methods and compositions using a nucleic acid molecule encoding an atonal-associated factor in combination with a co-transcription factor and/or inhibitor of a gene silencing complex to change the sensory perception of an animal are described.
    Type: Application
    Filed: March 16, 2022
    Publication date: August 11, 2022
    Applicant: St. Jude Children's Research Hospital
    Inventors: Jian Zuo, Fei Zheng, Tetsuji Yamashita, Wanda Layman
  • Patent number: 11406690
    Abstract: The present disclosure provides methods of generating multiplexed genetically modified animals, for example, porcine endogenous retrovirus (PERV)-inactivated pigs. The disclosure also provides methods of improving the birth rate of multiplexed genetically modified animals. In some embodiments, the present closure is concerned with the generation and utilization of porcine cells in which porcine endogenous retroviral (PERV) elements have been inactivated. In sonic embodiments, the PERV-free or PERV-reduced porcine cells are cloned to produce porcine embryos. In some embodiments, the PERV-free or PERV-reduced embryos may be grown into adult swine from which organs and/or tissues may be extracted and used for such purposes as xenotransplantation into non-porcine animals such as humans.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: August 9, 2022
    Assignees: BIOMARIN PHARMACEUTICAL INC., UCL BUSINESS LTD, ST. JUDE CHILDREN'S RESEARCH HOSPITAL
    Inventors: Peter Cameron Colosi, Amit Nathwani, Jenny McIntosh, Edward Tuddenham, Andrew Davidoff
  • Publication number: 20220226380
    Abstract: The present application provides methods of enhancing T cell function (e.g., expansion, persistence and/or effector functions), particularly by genetic modification of the Regnase-1, Batf, and additional genes (alone or in combination). The application also provides modified T cells manufactured using the methods provided by this invention and related pharmaceutical compositions. The application further provides methods of using the modified T cells for treating a disease (e.g., a cancer or an infectious disease).
    Type: Application
    Filed: April 23, 2020
    Publication date: July 21, 2022
    Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.
    Inventors: Hongbo CHI, Jun WEI, Terrence GEIGER, Wenting ZHENG
  • Publication number: 20220226379
    Abstract: The application provides modified immune effector cells wherein the DNA (cytosine-5)-methyltransferase 3A (DNMT3A)-mediated de novo DNA methylation of the cell genome is inhibited, and STAT5 signaling pathway is activated. The application also provides related pharmaceutical compositions and the methods for generating such modified immune effector cells. The application further provides uses of such modified immune effector cells for treating diseases such as cancers, infectious diseases and autoimmune diseases.
    Type: Application
    Filed: April 8, 2020
    Publication date: July 21, 2022
    Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.
    Inventors: Stephen GOTTSCHALK, Giedre KRENCIUTE, Christopher PETERSEN, Benjamin YOUNGBLOOD
  • Patent number: 11390658
    Abstract: A nucleic acid construct and mammalian cell harboring nucleic acids encoding an anti-CD7 chimeric antigen receptor are provided. Methods for treating cancer, in particular a hematologic cancer, using the nucleic acid construct or mammalian cell are also described.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: July 19, 2022
    Assignee: ST. JUDE CHILDREN'S RESEARCH HOSPITAL
    Inventors: Rafijul Bari, Wing Leung
  • Patent number: 11371095
    Abstract: The invention relates to a high-throughput method for characterizing the genome-wide activity of editing nucleases in vitro.
    Type: Grant
    Filed: February 3, 2021
    Date of Patent: June 28, 2022
    Assignee: St. Jude Children's Research Hospital, Inc.
    Inventors: Shengdar Q. Tsai, Cicera R. Lazzarotto
  • Publication number: 20220195007
    Abstract: The present disclosure provides chimeric antigen receptors (CARs), particularly CARs that have enhanced antitumor properties and/or can be regulated by safety switches. Also provided are polypeptides of the CARs and other related molecules, polynucleotides, vectors, and cell compositions comprising the same. Pharmaceutical compositions comprising the polypeptides, polynucleotides, vectors, or cells of the present disclosure, and their uses in treating a cancer in a subject are also provided.
    Type: Application
    Filed: April 10, 2020
    Publication date: June 23, 2022
    Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.
    Inventors: Mireya Paulina VELASQUEZ, Stephen GOTTSCHALK, Janice RIBERDY, Albert ZHOU, Byoung RYU, Abishek VAIDYA, Giedre KRENCIUTE
  • Patent number: 11331373
    Abstract: Methods and compositions using a nucleic acid molecule encoding an atonal-associated factor in combination with a co-transcription factor and/or inhibitor of a gene silencing complex to change the sensory perception of an animal are described.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: May 17, 2022
    Assignee: St. Jude Children's Research Hospital
    Inventors: Jian Zuo, Fei Zheng, Tetsuji Yamashita, Wanda Layman